{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T11:57:18Z","timestamp":1676030238408},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00115-021-01106-z","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T13:03:48Z","timestamp":1617195828000},"page":"317-333","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aquaporin-4-Antik\u00f6rper-positive-Neuromyelitis-optica-Spektrum-Erkrankungen und Myelinoligodendrozytenglykoprotein-Antik\u00f6rper-assoziierte Enzephalomyelitis. Eine Kurz\u00fcbersicht"],"prefix":"10.1007","volume":"92","author":[{"given":"Sven","family":"Jarius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"1106_CR1","volume-title":"Quality Manual Multiple Sklerose. Recommendations on the therapy of multiple sclerosis\/neuromyelitis optica spectrum disorders for physicians","author":"O Aktas","year":"2020","unstructured":"Aktas\u00a0O, Kleiter\u00a0I, K\u00fcmpfel\u00a0T et\u00a0al (2020) Practical aspects of diagnosis and therapy of neuromyelitis optica spectrum disorders. In: Quality Manual Multiple Sklerose. Recommendations on the therapy of multiple sclerosis\/neuromyelitis optica spectrum disorders for physicians. Krankheitsbezogenes Kompetenznetz Multiple Sklerose e.\u202fV., Munich"},{"key":"1106_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens\u00a0AL, Wendel\u00a0EM, Lechner\u00a0C et al (2020) E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29:41\u201353","journal-title":"Eur J Paediatr Neurol"},{"key":"1106_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen\u00a0JJ, Flanagan\u00a0EP, Jitprapaikulsan\u00a0J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8\u201315","journal-title":"Am J Ophthalmol"},{"key":"1106_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","volume":"136","author":"JJ Chen","year":"2018","unstructured":"Chen\u00a0JJ, Tobin\u00a0WO, Majed\u00a0M et al (2018) Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol 136:419\u2013422","journal-title":"JAMA Ophthalmol"},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","volume":"264","author":"A Cobo-Calvo","year":"2017","unstructured":"Cobo-Calvo\u00a0A, Ruiz\u00a0A, D\u2019indy\u00a0H et al (2017) MOG antibody-related disorders: common features and uncommon presentations. J\u00a0Neurol 264:1945\u20131955","journal-title":"J Neurol"},{"key":"1106_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"C Cree Ba","year":"2019","unstructured":"Cree Ba\u00a0C, Bennett\u00a0JL, Kim\u00a0HJ et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a\u00a0double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394:1352\u20131363","journal-title":"Lancet"},{"key":"1106_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","volume":"26","author":"CL De Mol","year":"2020","unstructured":"De Mol\u00a0CL, Wong\u00a0Y, Van Pelt\u00a0ED et al (2020) The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 26:806\u2013814","journal-title":"Mult Scler"},{"key":"1106_CR8","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1007\/s00415-020-10024-0","volume":"267","author":"M Gastaldi","year":"2020","unstructured":"Gastaldi\u00a0M, Scaranzin\u00a0S, Jarius\u00a0S et al (2020) Cell-based assays for the detection of MOG antibodies: a\u00a0comparative study. J\u00a0Neurol 267:3555\u20133564","journal-title":"J Neurol"},{"key":"1106_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","volume":"139","author":"R Hoftberger","year":"2020","unstructured":"Hoftberger\u00a0R, Guo\u00a0Y, Flanagan\u00a0EP et\u00a0al (2020) The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 139:875\u2013892","journal-title":"Acta Neuropathol"},{"key":"1106_CR10","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius\u00a0S, Aboul-Enein\u00a0F, Waters\u00a0P et al (2008) Antibody to aquaporin\u20114 in the long-term course of neuromyelitis optica. Brain 131:3072\u20133080","journal-title":"Brain"},{"key":"1106_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00415-016-8360-4","volume":"264","author":"S Jarius","year":"2017","unstructured":"Jarius\u00a0S, Eichhorn\u00a0P, Franciotta\u00a0D et al (2017) The MRZ reaction as a\u00a0highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J\u00a0Neurol 264:453\u2013466","journal-title":"J Neurol"},{"key":"1106_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/jnnp.2007.133330","volume":"79","author":"S Jarius","year":"2008","unstructured":"Jarius\u00a0S, Franciotta\u00a0D, Bergamaschi\u00a0R et\u00a0al (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J\u00a0Neurol Neurosurg Psychiatry 79:1134\u20131136","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1106_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","volume":"298","author":"S Jarius","year":"2010","unstructured":"Jarius\u00a0S, Frederikson\u00a0J, Waters\u00a0P et al (2010) Frequency and prognostic impact of antibodies to aquaporin\u20114 in patients with optic neuritis. J\u00a0Neurol Sci 298:158\u2013162","journal-title":"J Neurol Sci"},{"key":"1106_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius\u00a0S, Kleiter\u00a0I, Ruprecht\u00a0K et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50\u00a0patients. Part 3: Brainstem involvement\u2014frequency, presentation and outcome. J\u00a0Neuroinflammation 13:281","journal-title":"J Neuroinflammation"},{"key":"1106_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","volume":"17","author":"S Jarius","year":"2020","unstructured":"Jarius\u00a0S, Lechner\u00a0C, Wendel\u00a0EM et\u00a0al (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. J\u00a0Neuroinflammation 17:262","journal-title":"J Neuroinflammation"},{"key":"1106_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius\u00a0S, Paul\u00a0F, Aktas\u00a0O et\u00a0al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J\u00a0Neuroinflammation 15:134","journal-title":"J Neuroinflammation"},{"key":"1106_CR17","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","volume":"89","author":"S Jarius","year":"2018","unstructured":"Jarius\u00a0S, Paul\u00a0F, Aktas\u00a0O et\u00a0al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Nervenarzt 89:1388\u20131399","journal-title":"Nervenarzt"},{"key":"1106_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius\u00a0S, Paul\u00a0F, Franciotta\u00a0D et al (2011) Cerebrospinal fluid findings in aquaporin\u20114 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J\u00a0Neurol Sci 306:82\u201390","journal-title":"J Neurol Sci"},{"key":"1106_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncpneuro0764","volume":"4","author":"S Jarius","year":"2008","unstructured":"Jarius\u00a0S, Paul\u00a0F, Franciotta\u00a0D et al (2008) Mechanisms of disease: aquaporin\u20114 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202\u2013214","journal-title":"Nat Clin Pract Neurol"},{"key":"1106_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius\u00a0S, Paul\u00a0F, Weinshenker\u00a0BG et\u00a0al (2020) Neuromyelitis optica. Nat Rev Dis Primers 6:85","journal-title":"Nat Rev Dis Primers"},{"key":"1106_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","volume":"17","author":"S Jarius","year":"2020","unstructured":"Jarius\u00a0S, Pellkofer\u00a0H, Siebert\u00a0N et\u00a0al (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J\u00a0Neuroinflammation 17:261","journal-title":"J Neuroinflammation"},{"key":"1106_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","volume":"291","author":"S Jarius","year":"2010","unstructured":"Jarius\u00a0S, Probst\u00a0C, Borowski\u00a0K et al (2010) Standardized method for the detection of antibodies to aquaporin\u20114 based on a\u00a0highly sensitive immunofluorescence assay employing recombinant target antigen. J\u00a0Neurol Sci 291:52\u201356","journal-title":"J Neurol Sci"},{"key":"1106_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius\u00a0S, Ruprecht\u00a0K, Kleiter\u00a0I et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50\u00a0patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J\u00a0Neuroinflammation 13:280","journal-title":"J Neuroinflammation"},{"key":"1106_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius\u00a0S, Ruprecht\u00a0K, Kleiter\u00a0I et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50\u00a0patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J\u00a0Neuroinflammation 13:279","journal-title":"J Neuroinflammation"},{"key":"1106_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius\u00a0S, Ruprecht\u00a0K, Wildemann\u00a0B et\u00a0al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175\u00a0patients. J\u00a0Neuroinflammation 9:14","journal-title":"J Neuroinflammation"},{"key":"1106_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang\u00a0C, Zhang\u00a0M, Qiu\u00a0W et al (2020) Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19:391\u2013401","journal-title":"Lancet Neurol"},{"key":"1106_CR27","doi-asserted-by":"crossref","unstructured":"Jarius\u00a0S, Wandinger\u00a0KP, Borowski\u00a0K, Stoecker\u00a0W, Wildemann\u00a0B (2012). Antibodies to CV2\/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 114(4):331-5.","DOI":"10.1016\/j.clineuro.2011.10.048"},{"key":"1106_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius\u00a0S, Wildemann\u00a0B (2010) AQP4 antibodies in neuromyelitis optica: pathogenic and diagnostic relevance. Nat Rev Neurol 6:383\u2013392","journal-title":"Nat Rev Neurol"},{"key":"1106_CR29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bpa.12084","volume":"23","author":"S Jarius","year":"2013","unstructured":"Jarius\u00a0S, Wildemann\u00a0B (2013) Aquaporin\u20114 antibodies (NMO-IgG) as a\u00a0serological marker of neuromyelitis optica: a\u00a0critical review of the literature. Brain Pathol 23:661\u2013683","journal-title":"Brain Pathol"},{"key":"1106_CR30","doi-asserted-by":"publisher","first-page":"116396","DOI":"10.1016\/j.jns.2019.07.014","volume":"407","author":"S Jarius","year":"2019","unstructured":"Jarius\u00a0S, Wildemann\u00a0B (2019) Devic\u2019s index case: a critical reappraisal\u2014AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis? J\u00a0Neurol Sci 407:116396","journal-title":"J Neurol Sci"},{"key":"1106_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","volume":"10","author":"S Jarius","year":"2013","unstructured":"Jarius\u00a0S, Wildemann\u00a0B (2013) The history of neuromyelitis optica. J\u00a0Neuroinflammation 10:8","journal-title":"J Neuroinflammation"},{"key":"1106_CR32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-019-1594-1","volume":"16","author":"S Jarius","year":"2019","unstructured":"Jarius\u00a0S, Wildemann\u00a0B (2019) The history of neuromyelitis optica. Part 2: \u2018Spinal amaurosis\u2019, or how it all began. J\u00a0Neuroinflammation 16:280","journal-title":"J Neuroinflammation"},{"key":"1106_CR33","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","volume":"5","author":"I Kleiter","year":"2018","unstructured":"Kleiter\u00a0I, Gahlen\u00a0A, Borisow\u00a0N et\u00a0al (2018) Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 5:e504","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1106_CR34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","volume":"79","author":"I Kleiter","year":"2016","unstructured":"Kleiter\u00a0I, Gahlen\u00a0A, Borisow\u00a0N et\u00a0al (2016) Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 79:206\u2013216","journal-title":"Ann Neurol"},{"key":"1106_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon\u00a0VA, Kryzer\u00a0TJ, Pittock\u00a0SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin\u20114 water channel. J\u00a0Exp Med 202:473\u2013477","journal-title":"J Exp Med"},{"key":"1106_CR36","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon\u00a0VA, Wingerchuk\u00a0DM, Kryzer\u00a0TJ et\u00a0al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"key":"1106_CR37","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti\u00a0CF, Mandler\u00a0RN, Mcgavern\u00a0D et\u00a0al (2002) A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125:1450\u20131461","journal-title":"Brain"},{"key":"1106_CR38","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader\u00a0S, Gredler\u00a0V, Schanda\u00a0K et\u00a0al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J\u00a0Neuroinflammation 8:184","journal-title":"J Neuroinflammation"},{"key":"1106_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","volume":"16","author":"Y Mao-Draayer","year":"2020","unstructured":"Mao-Draayer\u00a0Y, Thiel\u00a0S, Mills\u00a0EA et al (2020) Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol 16:154\u2013170","journal-title":"Nat Rev Neurol"},{"key":"1106_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache\u00a0F, Zimmermann\u00a0H, Mikolajczak\u00a0J et al (2016) MOG-IgG in NMO and related disorders: a\u00a0multicenter study of 50\u00a0patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J\u00a0Neuroinflammation 13:282","journal-title":"J Neuroinflammation"},{"key":"1106_CR41","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","volume":"67","author":"J Palace","year":"2010","unstructured":"Palace\u00a0J, Leite\u00a0MI, Nairne\u00a0A et\u00a0al (2010) Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67:1016\u20131017","journal-title":"Arch Neurol"},{"key":"1106_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.38.2.180","volume":"38","author":"DW Paty","year":"1988","unstructured":"Paty\u00a0DW, Oger\u00a0JJ, Kastrukoff\u00a0LF et\u00a0al (1988) MRI in the diagnosis of MS: a\u00a0prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 38:180\u2013185","journal-title":"Neurology"},{"key":"1106_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock\u00a0SJ, Berthele\u00a0A, Fujihara\u00a0K et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N\u00a0Engl J Med 381:614\u2013625","journal-title":"N Engl J Med"},{"key":"1106_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","volume":"30","author":"M Reindl","year":"2017","unstructured":"Reindl\u00a0M, Jarius\u00a0S, Rostasy\u00a0K et\u00a0al (2017) Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol 30:295\u2013301","journal-title":"Curr Opin Neurol"},{"key":"1106_CR45","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1212\/WNL.0000000000008684","volume":"94","author":"M Ringelstein","year":"2020","unstructured":"Ringelstein\u00a0M, Harmel\u00a0J, Zimmermann\u00a0H et al (2020) Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology 94:e407\u2013e418","journal-title":"Neurology"},{"key":"1106_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2051-5960-2-35","volume":"2","author":"S Saadoun","year":"2014","unstructured":"Saadoun\u00a0S, Waters\u00a0P, Owens\u00a0GP et al (2014) Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. acta neuropathol commun 2:35","journal-title":"acta neuropathol commun"},{"key":"1106_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.25291","volume":"84","author":"M Spadaro","year":"2018","unstructured":"Spadaro\u00a0M, Winklmeier\u00a0S, Beltran\u00a0E et\u00a0al (2018) Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol 84:315\u2013328","journal-title":"Ann Neurol"},{"key":"1106_CR48","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"JP Stellmann","year":"2017","unstructured":"Stellmann\u00a0JP, Krumbholz\u00a0M, Friede\u00a0T et\u00a0al (2017) Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J\u00a0Neurol Neurosurg Psychiatry 88:639\u2013647","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1106_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara\u00a0M, Oeda\u00a0T, Okada\u00a0K et al (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1\u00a0study): a\u00a0multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298\u2013306","journal-title":"Lancet Neurol"},{"key":"1106_CR50","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/brain\/awaa102","volume":"143","author":"Y Takai","year":"2020","unstructured":"Takai\u00a0Y, Misu\u00a0T, Kaneko\u00a0K et al (2020) Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 143:1431\u20131446","journal-title":"Brain"},{"key":"1106_CR51","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s00115-010-3192-4","volume":"82","author":"C Trebst","year":"2011","unstructured":"Trebst\u00a0C, Berthele\u00a0A, Jarius\u00a0S et\u00a0al (2011) Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group. Nervenarzt 82:768\u2013777","journal-title":"Nervenarzt"},{"key":"1106_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst\u00a0C, Jarius\u00a0S, Berthele\u00a0A et\u00a0al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J\u00a0Neurol 261:1\u201316","journal-title":"J Neurol"},{"key":"1106_CR53","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","volume":"87","author":"P Waters","year":"2016","unstructured":"Waters\u00a0P, Reindl\u00a0M, Saiz\u00a0A et al (2016) Multicentre comparison of a\u00a0diagnostic assay: aquaporin\u20114 antibodies in neuromyelitis optica. J\u00a0Neurol Neurosurg Psychiatry 87:1005\u20131015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1106_CR54","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","volume":"44","author":"DH Whittam","year":"2020","unstructured":"Whittam\u00a0DH, Cobo-Calvo\u00a0A, Lopez-Chiriboga\u00a0AS et al (2020) Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121\u00a0patients. Mult Scler Rel Dis 44:102251","journal-title":"Mult Scler Rel Dis"},{"key":"1106_CR55","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1055\/a-1219-7907","volume":"237","author":"B Wildemann","year":"2020","unstructured":"Wildemann\u00a0B, Horstmann\u00a0S, Korporal-Kuhnke\u00a0M et al (2020) Aquaporin\u20114 and myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: diagnosis and treatment. Klin Monbl Augenheilkd 237:1290\u20131305","journal-title":"Klin Monbl Augenheilkd"},{"key":"1106_CR56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00401-020-02236-5","volume":"141","author":"B Wildemann","year":"2021","unstructured":"Wildemann\u00a0B, Jarius\u00a0S, Franz\u00a0J et al (2021) MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis. Acta Neuropathol 141:127\u2013131","journal-title":"Acta Neuropathol"},{"key":"1106_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1212\/WNL.0000000000004087","volume":"89","author":"B Wildemann","year":"2017","unstructured":"Wildemann\u00a0B, Jarius\u00a0S, Schwarz\u00a0A et\u00a0al (2017) Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology 89:207\u2013209","journal-title":"Neurology"},{"key":"1106_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk\u00a0DM, Banwell\u00a0B, Bennett\u00a0JL et\u00a0al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"1106_CR59","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk\u00a0DM, Hogancamp\u00a0WF, O\u2019brien\u00a0PC et\u00a0al (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53:1107\u20131114","journal-title":"Neurology"},{"key":"1106_CR60","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk\u00a0DM, Lennon\u00a0VA, Pittock\u00a0SJ et\u00a0al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"1106_CR61","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura\u00a0T, Kleiter\u00a0I, Fujihara\u00a0K et\u00a0al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N\u00a0Engl J Med 381:2114\u20132124","journal-title":"N Engl J Med"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-021-01106-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T03:50:26Z","timestamp":1675137026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-021-01106-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01106-z","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"25 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Jarius gibt an, dass kein Interessenkonflikt besteht. B.\u00a0Wildemann erhielt Forschungsunterst\u00fctzung durch das Bundesministerium f\u00fcr Bildung und Forschung, die Deutsche Forschungsgemeinschaft, die Dietmar-Hopp-Stiftung, die Klaus-Tschira-Stiftung, Forschungsunterst\u00fctzung und Honorare f\u00fcr Vortragst\u00e4tigkeiten von Merck Serono, Sanofi Genzyme, Novartis, and Honorare f\u00fcr Vortragst\u00e4tigkeiten von Alexion, Bayer, Biogen, Teva, alle ohne direkten Bezug zu dieser Arbeit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}